Rigel Pharma Balance Sheet - Annual (NASDAQ:RIGL)

Add to My Stocks
$3.32 $0.27 (7.52%) RIGL stock closing price Sep 20, 2018 (Closing)

A thorough fundamental analysis involves using data from Rigel Pharma balance sheet, apart from other financial statements, to value the business. Balance sheet items like cash at hand, total assets and liabilities helps one analyze a company and summarize the financial performance of the company like we have in our Rigel Pharma stock analysis. Annual results are typically accompanied with the company releasing financial statements. Rigel Pharma had a long term debt of $- at the end of 2017. To understand the debt servicing capacity of the company, one needs to look at Rigel Pharma operating cash flow and Rigel Pharma revenue also. Rigel Pharma debt to equity ratio is 0.

View latest 10 year balance sheet data to check Rigel Pharma financial performance.
show more
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011201020092008
Marketable Securities77.46M57.13M82.82M127.95M191.12M264.75M229M168.41M118.6M88.47M
Raw Materials----------
Work In Progress----------
Finished Goods----------
Notes Receivable----------
Other Current Assets1.68M1.44M2.54M1.62M2.35M4.21M2.59M2.63M2.65M3.61M
Total Current Assets
Property Plant & Equipment13.15M19.94M19.76M25.63M26.83M26.06M23.1M21M18.33M19.02M
Accumulated Depreciation12.27M18.79M18.15M23.12M22.38M20.23M18.22M16.47M16.04M15.45M
Net Property Plant & Equipment
Investment & Advances----------
Other Non-Current Assets----------
Deferred Charges----------
Deposits & Other Assets--1.11M1.08M1.52M1.75M1.99M2.23M2.48M2.2M
Total Assets
Notes Payable----------
Accounts Payable2.63M5.56M2.76M1.61M3.9M1.69M1.55M1.4M3.15M5.98M
Current Portion Long-Term Debt----------
Current Portion Capital Leases-3.22M3M2.8M----1.06M1.33M
Accrued Expenses15.41M10.99M12.33M7.35M5.18M9.84M9.84M9.16M13.55M13.65M
Income Taxes Payable----------
Other Current Liabilities-2.8M15.69M2.25M1.2M----3.17M
Total Current Liabilities
Deferred Taxes/Income--3.08M5.34M7.43M8.64M9.31M9.05M12.06M13.31M
Convertible Debt----------
Long-Term Debt----------
Non-Current Capital Leases--3.46M6.46M-----2.05M
Other Long-Term Liabilities----------
Total Liabilities
Minority Interest----------
Preferred Stock----------
Common Stock Net----------
Capital Surplus1.24B1.12B1.08B1.07B1.06B1.05B897.47M741.55M723.15M605.5M
Retained Earnings-1.14B-1.06B-991.64M-940.18M-849.27M-760.24M-661.4M-575.43M-613.32M-501.77M
Treasury Stock----------
Other Liabilities-0.08M-0.01M-0.04M-0.01M----0.03M-0.01M-
Shareholders Equity100.64M55.02M91.38M128.24M208.25M289.09M236.14M166.13M109.86M104.16M
Total Liabilities & Shareholders Equity119.11M78.13M131.74M154.13M226.05M310.04M257.1M186.69M140.74M143.85M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Apart from balance sheet items, an investor would do well to keep track of the Rigel Pharma stock price by looking at Rigel Pharma historical stock prices. One can compare PE with industry average by looking at the Rigel Pharma PE ratio chart. The common balance sheet items are:

  • Assets: RIGL total assets, which was at $119.11M for 2017 is a balance sheet item representing value of what Rigel Pharma owns. Assets are brought to aid a firms operations, or to increase its economic value. It must be noted that tech stocks may not have a lot of assets, as the value for these companies is often derived from future earning potential.
  • Liabilities: This item on the balance sheet implies the firm's, in this case Rigel Pharma's, legal obligations including loans, accounts payable, deferred revenue, accrued expenses and mortgages. The total liabilities for RIGL stock stand at $18.46M.

Rigel Pharma Balance Sheet - Key Ratios

Current ratio
Debt to equity ratio
Asset turnover ratio
Receivables turnover
Price to book ratio